ALK is an inclusion eligibility criterion in 1 clinical trial for central nervous system lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and central nervous system lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BRD3 is an inclusion eligibility criterion in 1 clinical trial for central nervous system lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BRD3 status and central nervous system lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BRD4 is an inclusion eligibility criterion in 1 clinical trial for central nervous system lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BRD4 status and central nervous system lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MYC is an inclusion eligibility criterion in 1 clinical trial for central nervous system lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and central nervous system lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MYCN is an inclusion eligibility criterion in 1 clinical trial for central nervous system lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and central nervous system lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].